Premium
Indian drugmaker Cipla revived its inorganic expansion strategy in 2013 and has been pursuing acquisitions at a frenetic pace since then. The firm has announced acquisition deals worth well over $1 billion in the past three years alone.With a fresh look at investing in China, it is not finished yet. ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
